GEN Webinar: Speed and Simplicity for mRNA Vaccines and Therapeutics CQA Testing

Register to view the webinar

Speaker: Kathy Rowlen, PhD

Title: CEO & Co-founder InDevR

Bio: Dr. Kathy Rowlen has more than 20 years of management and research experience in business and academics, with more than 10 years in the field of biotechnology. Rowlen was a successful Professor of Chemistry at the University of Colorado in Boulder from 1991 to 2008. After co-founding InDevR in 2003 and serving as its Chief Science Officer, she transitioned to a full-time position as InDevR’s CEO in 2008. Dr. Rowlen has a well-earned reputation as a resourceful business entrepreneur and has raised substantial non-dilutive funding. Under her leadership, InDevR has demonstrated excellence in translating innovative ideas into high-impact commercial products.

About This Webinar

The valiant effort to develop mRNA-based vaccines against pandemic coronavirus was not only successful but safe and efficacious vaccines were achieved in record time. While the analytical tools used to verify the critical quality attributes (CQA) of mRNA vaccines played a vital role in that success, there is a widely acknowledged need for more cost and labor-efficient methods. Furthermore, developing the new generation of multivalent mRNA vaccines poses additional challenges. The multiplexed VaxArray Platform is ideally suited to address the need for rapid and accurate verification of the identity, quantity, and stability of mRNA vaccines and therapeutics, including multivalent drug products.

In this GEN webinar, our distinguished guest, Dr. Kathy Rowlen, will detail the performance characteristics of a VaxArray Assay for multivalent influenza mRNA formulations that include constructs for both hemagglutinin and neuraminidase. Dr. Rowlen will also show us data demonstrating assay specificity, sensitivity, accuracy, and precision for both “naked” and lipid-encapsulated mRNA. In addition, the total assay time is less than 2 hours, with no need for deformulation or extraction, resulting in the desired cost and speed efficiency for mRNA CQA testing.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.